PRISE EN CHARGE DES TUMEURS EPITHELIALES THYMIQUES

Combined Modality Therapy; Humans; Neoplasms, Glandular and Epithelial/pathology/therapy; Thymus Neoplasms/pathology/therapy; thymome; traitement; chimiothérapie

Abstract :

[en] Thymic epithelial tumors (TET) are rare. Their optimal care is still poorly defined because of their rarity and of the resulting difficulty to conceive large clinical trials. This review of the literature presents the current clinical and therapeutic data on this form of tumors and underlines the need for a multidisciplinary approach to advanced stage TET. Three clinical situations can be encountered: encapsuled tumors lead to radical surgery; tumors associated with capsular invasion justify a postoperative radiotherapy; advanced stages require a multimodal treatment by chemotherapy, possibly completed by surgery and adjuvant radiotherapy. Besides systemic chemotherapies, the place of new therapeutic strategies, such as somatostatin analogues and targeted treatments, requires to be defined. Treatment of late stage TET is based upon a multidisciplinary dialogue, ideally by a reference team.
[fr] Résumé : Les tumeurs épithéliales thymiques (TET) sont des tumeurs rares. Leur prise en charge optimale est encore mal définie du fait de leur rareté et, donc, de la difficulté de réaliser des essais cliniques portant sur de larges cohortes. Cette revue de la littérature présente les données cliniques et thérapeutiques actuelles, en insistant sur la nécessité d’une prise en charge pluridisciplinaire des TET de stade avancé. Trois situations cliniques peuvent se rencontrer : les tumeurs encapsulées, relevant d’une chirurgie radicale, les tumeurs associées à une invasion capsulaire qui justifient une radiothérapie postopératoire et les TET de stade avancé qui nécessitent un traitement multimodal par chimiothérapie, éventuellement complétée par une chirurgie et radiothérapie adjuvante. A côté des traitements systémiques de chimiothérapie, l’apport des nouvelles thérapeutiques, comme les analogues de la somatostatine et les traitements ciblés, mérite d’être précisé. La prise en charge des TET de stade avancé doit reposer sur une concertation multidisciplinaire, idéalement par une équipe de référence. Mots-clés : Thymome - Traitement - Chimiothérapie

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

PAULUS, Astrid ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

SIBILLE, Anne ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

BOURHABA, Maryam ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

MARTIN, Marie ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

LOUIS, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

DUYSINX, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Language :

French

Title :

PRISE EN CHARGE DES TUMEURS EPITHELIALES THYMIQUES

Alternative titles :

[en] MANAGEMENT OF THYMIC EPITHELIAL TUMORS

Publication date :

December 2015

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

623-8

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be/

Available on ORBi :

since 08 April 2016

Statistics

Number of views

232 (8 by ULiège)

Number of downloads

761 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Arpin D, Aubert A, Aubert M, et al. -Les Tumeurs Epithéliales Thymiques. Référentiel en oncologie Rhône-Alpes-Auvergne/RYTHMIC, 2011, 27.
Perrotin C, Régnard JF. -Tumeurs du thymus, EMC. Pneumologie, 2005, 2, 33-48.
Bezjak A, Meneshian A, Giaccone G. -Clinical presentation and management of thymoma and thymic carcinoma, www.UpToDate.com, (consultation du 03/12/2013).
Engels EA, Pfeiffer RM. -Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer, 2003, 105, 546-551.
Rosai J. -Histological typing of tumours of the thymus. Springer-Verlag, New York, 2nd ed, 1999.
Okumura M, Ohta M, Tateyama H, et al. -The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer, 2002, 94, 624-632.
Masaoka A, Monden Y, Nakahara K, Tanioka T. -Followup study of thymomas with special reference to their clinical stages. Cancer, 1981, 48, 2485-2492.
Le Péchoux C, Mahé M, Bretel JJ, et al. -Thymic tumors. Cancer Radiother, 2005, 9, 351-357.
Ruffie P, Gory-Delabaere G, Fervers B, et al. -Standards, options et recommandations pour la prise en charge des patients atteints de tumeurs épithéliales du thymus. Groupe de travail SOR. Bull Cancer, 1999, 86, 365-384.
Curran WJ Jr, Kornstein MJ, Brooks JJ, et al. -Invasive thymoma: The role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol, 1988, 6, 1722-1727.
Hejna M, Haberl I, Raderer M. -Non surgical management of malignant thymoma. Cancer, 1999 , 85 , 1871-1884.
Koga K, Matsuno Y, Noguchi M, et al. -A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int, 1994, 44, 359-367.
Kondo K, Yoshizawa K, Tsuyuguchi M, et al. -WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg, 2004, 77, 1183-1188.
Jacot W, Quantin X, Pujol JL. -Traitement des tumeurs épithéliales thymiques. Vers une prise en charge pluridisciplinaire. Rev Mal Respir, 2006, 23, 3S35-3S46.
Kondo K, Monden Y. -Therapy for thymic epithelial tumors: A clinical study of 1.320 patients from Japan. Ann Thorac Surg, 2003, 76, 878-884.
Marx A, Ströbel P, Badve SS, et al. -ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol, 2014, 9, 596-611.
Girard N, Mornex F, Van Houtte P, et al. -Thymoma: a focus on current therapeutic management. J Thorac Oncol, 2009, 4, 119-126.
Davenport E1, Malthaner RA. -The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg, 2008, 86, 673-684.
Toker A, Sonett J, Zielinski M, et al. -Standard terms, definitions, and policies for minimally invasive resection of thymoma. J Thorac Oncol, 2011, 6, S1739-S1742.
Forquer JA1, Rong N, Fakiris AJ, et al. -Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys, 2010, 76 , 440-445.
Fernandes AT1, Shinohara ET, Guo M et al. -The role of radiation therapy in malignant thymoma: a surveillance, epidemiology, and end results database analysis. J Thorac Oncol, 2010, 5, 1454-1460.
Mangi AA, Wright CD, Allan JS, et al. -Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg, 2002, 74, 1033-1037.
Moiseenko V, Craig T, Bezjak A, et al. -Dose-volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review. Radiother Oncol, 2003, 67, 265-274.
Loehrer PJ Sr1, Kim K, Aisner SC, et al. -Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol, 1994, 12, 1164-1168.
Berruti A1, Borasio P, Gerbino A, et al. -Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer, 1999, 81, 841-845.
Loehrer PJ Sr1, Chen M, Kim K, et al. -Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol, 1997, 15, 3093-3099.
Giaccone G, Ardizzoni A, Kirkpatrick A, et al. -Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol, 1996, 14, 814-820.
Lemma GL, Lee JW, Aisner SC, et al. -Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol, 2011, 29, 2060-2065.
Hirai F, Yamanaka T, Taguchi K, et al. -A multicenter phase II study of carboplastin and placlitaxel for advanced thymic carcinoma: WJOG 4207 L. Ann Oncol, 2015, 26, 363-368.
Gordon MS1, Battiato LA, Gonin R, et al. -A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed/refractory thymoma. J Immunother Emphasis Tumor Immunol, 1995, 18, 179-184.
Loehrer PJ Sr1, Wang W, Johnson DH, et al.; Eastern Cooperative Oncology Group Phase II Trial. -Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an eastern cooperative oncology group phase II trial. J Clin Oncol, 2004, 22, 293-299.
Ronan Joseph Kelly MD, MBA. -Systemic treatment of advanced thymic malignancies. American Society of Clinical Oncology. Educational Book, 2014.
Kurup A, Burns M, Dropcho S, et al. -Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol, 2005, 23, 165.
Giaccone G1, Rajan A, Ruijter R, et al. -Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol, 2009, 4, 1270-1273.
Salter JT, Lewis D, Yiannoutsos C, et al. -Imatinib for the treatment of thymic carcinoma. J Clin Oncol, 2008, 26, 8116.
Ströbel P1, Bargou R, Wolff A, et al. -Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer, 2010, 103, 196-200.
Detterbeck FC, Asamura H, Crowley J, et al. -The IASLC/ ITMIG thymic malignacies staging project. Development of a stage classification of thymic malignancies. JTO, 2013, 8, 1467-1473.